Evidence map›Paper›PMID 42681668›Full record

ArticleBMC medicine2026

Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies.

Michael Siebers, Dana Huvermann, Christoph Siebers, Deborah Canales-Romero, Alexandra Florea-Ghile, Lina Keite, Lucas John, Moritz Munk, Roman Bizjak, Jens Witzel and 8 more

Abstract read
In one paragraph

Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michael SiebersInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany. Michael.Siebers@LVR.de.ORCID 0000-0002-1400-2176
Dana HuvermannInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.
Christoph SiebersInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.
Deborah Canales-RomeroInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.
Alexandra Florea-GhileDepartment of Psychiatry and Psychotherapy, Center for Translational Neuro- and Behavioral Sciences, LVR University Hospital Essen, University of Duisburg- Essen, Essen, Germany.
Lina KeiteInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.
Lucas JohnDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Moritz MunkDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Roman BizjakDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Jens WitzelDepartment of Central IT, Division Applications and Databases, University of Zurich, Zurich, Switzerland.
Sebastian SchulzDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Johannes KirstenDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Laura BindilaClinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Anke HinneySection of Molecular Genetics in Mental Disorders, Center for Translational Neuro- and Behavioral Sciences, Institute of Sex and Gender-Sensitive Medicine, University of Duisburg-Essen, Essen, Germany.
Marijke GrauInstitute of Cardiovascular Research and Sports Medicine, Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany.
Daniel A BizjakDepartment of Internal Medicine, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany.
Harald EnglerInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Johannes FussInstitute for Forensic Psychiatry and Sexual Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocannabinoid (eCB) signaling has been implicated in the physiological and affective responses to endurance exercise, including phenomena such as the runner's high. However, although humans have the capacity to run for several hours and even days, evidence regarding eCB signaling is largely limited to exercise bouts shorter than 60 min. Consequently, the temporal dynamics of eCB signaling during prolonged running and the accompanying acute affective responses remain unclear.

methodsThis study investigated eCB signaling during long-distance running and following a 45-minute break. Two studies were conducted: In Study 1, 19 trained runners completed both a marathon and a duration-matched walking session, with repeated blood sampling every 14 km during the marathon and after a 45-minute recovery. In Study 2, 36 ultramarathon runners completed races of 100 km, 160 km, or 230 km and provided blood samples before and after their respective races. Plasma concentrations of anandamide (AEA), 2-arachidonoylglycerol (2-AG), 1-AG, arachidonic acid (AA), and palmitoylethanolamide (PEA) were quantified by a standardized liquid chromatography/multiple reaction monitoring assay. Euphoria, anxiety, and pain were assessed as core features of the runner's high using visual analog scales.

resultsAEA increased progressively throughout the marathon and remained elevated after 45 min, whereas walking elicited only modest changes. In line, after all ultramarathon distances AEA levels were increased compared with baseline. By contrast, an increase in 2-AG during exercise was observed only in the regular marathon, where concentrations rose significantly during the later stages of running and into early recovery. Elevated post-race 2-AG levels were also observed following all ultramarathon distances, consistent with a delayed, recovery-related response. Marathon running was associated with higher euphoria and lower anxiety than walking, while pain increased after 28 km of running. Ultramarathon running increased pain, reduced anxiety, and did not significantly alter euphoria post-exercise.

conclusionsTogether, these findings show robust, time-dependent changes in circulating eCB concentrations during and after prolonged endurance running, as well as gradual increases in AEA during walking. These eCB dynamics occurred alongside acute affective changes during sustained endurance exercise.

Indexed as

EndocannabinoidsMarathon RunningPhysical EnduranceRunningAdultArachidonic AcidsFemaleHumansMaleMiddle AgedPolyunsaturated AlkamidesPost-Exercise RecoveryanandamideArachidonic AcidsEndocannabinoidsPolyunsaturated AlkamidesEndocannabinoid systemEndurance exerciseMood regulationNeuromodulationPhysical activityRunner’s high

Identifiers

PMID42681668
PMCPMC13531787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.